Currently, most antimetabolites are aimed at specific molecular targets of glycolysis, such as GLUT: blocking it can prevent glycolysis products from entering cancer cells, completely destroying the glycolysis pathways, and another common means of inhibiting glycolysis is targeting its key enzymes [30]. This evidence concerns the gene SLC2A1 and cancer.